Medicare AdvantageCoverageMedium impact
MA08.045n, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
Independence Blue Cross·Rheumatology, Oncology, Gastroenterology +1 more·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.045n for Tocilizumab and related biosimilars (intravenous infusion and subcutaneous injection) has been updated with changes effective October 1, 2025. This affects billing and coverage for this rheumatoid arthritis and other inflammatory condition medication.
Action Required
By October 1, 2025: Billing team must review updated policy MA08.045n for Tocilizumab and related biosimilars to understand any changes in coverage criteria, prior authorization requirements, or billing procedures for Medicare Advantage patients receiving these medications. Access the full policy details from the source URL to identify specific billing requirements.